


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patent
Washington, D.C. 20231

Atty. Dkt.: CL001187

Date: March 27, 2001

Sir:



JP229 U.S. PTO
09/01/199
03/27/01

Attached for filing is the patent application of:

Inventor: SHAO e tal

Entitled: **ISOLATED HUMAN RAS-LIKE PROTEINS, NUCLEIC ACID
MOLECULES ENCODING THESE HUMAN RAS-LIKE
PROTEINS, AND USES THEREOF**

and including attachments as noted below:

- ☒ Declaration, ☒ Abstract
66 pages of specification; Sequence Listing and claims (including 23 numbered claims), and
11 sheets of accompanying drawing/s.
☐ Record & return the attached assignment to the undersigned.

Priority is hereby claimed under 35 U.S.C 119 based on the following foreign applications, the entire content of which is hereby incorporated by reference in this application:

Application Number	Country	Day/Month/Year Filed
, respectively.		

☐ Certified copy(ies) of foreign application(s) is/are attached.
☐ Please amend the specification by inserting before the first line --This is a of-PCT application, filed

Priority is hereby claimed under 35 U.S.C 120/365 based on the following prior PCT applications designating the U.S., the entire content of which is hereby incorporated by reference in this application:

Application Number	Country	Day/Month/Year Filed
This application is based on the following prior provisional application(s):		

Application No.	Filing Date
respectively, the entire content of which is hereby incorporated by reference in this application, and priority is hereby claimed therefrom.	

Please amend the specification by inserting before the first line: --This application claims the benefit of U.S. Provisional Application No. , filed , the entire content of which is hereby incorporated by reference in this application.--

Verified Statement attached establishing "small entity" status (Rules 9 & 27)
The Examiner's attention is directed to the prior art cited in the parent application by applicant and/or Examiner for the reasons stated therein.

Preliminary amendment to claims (attached hereto), to be entered before calculation of the fee below.
Also attached: **Sub of Computer Readable Sequence Listing Diskette**

FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY HEREWITH CANCELED

Basic Filing Fee			
Total effective claims	23	- 20 (at least 20) =	3 x \$ 18.00
Independent claims	6	- 3 (at least 3) =	3 x \$ 80.00
If any proper multiple dependent claims now added for first time, add \$260.00 (ignore improper)			
If "small entity," then enter half (1/2) of subtotal and subtract			SUBTOTAL \$ 1004.00
Assignment Recording Fee (\$40.00)			SECOND SUBTOTAL \$ 1004.00
TOTAL FEE CHARGED TO DEPOSIT ACCOUNT			\$ 1,004.00

Any future submission requiring an extension of time is hereby stated to include a petition for such time extension.
The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Account No. 50-0970**. A duplicate copy of this sheet is attached.

CELERA Genomics Corporation
45 West Gude Drive, C2-4#20
Rockville, MD 20850
Telephone # 240-453-3067
JDK:pd

CELERA GENOMICS Corporation
By Atty: Justin D. Karjala, Reg. No. 43,704

Signature: